Skip to main content
. 2019 Nov 2;9(3):349–368. doi: 10.1016/j.jcmgh.2019.10.010

Figure 4.

Figure 4

Bemcentinib reduces liver fibrosis and inflammation in HFD-fed mice. (A) Body and liver weight, (B) triglycerides in liver extracts, and (C) serum alanine aminotransferase (ALT) transaminases were measured after sacrifice in mice fed for 8 weeks with chow or HFD that received vehicle or bemcentinib (BGB324) oral gavages for the last 2 weeks (n = 5–14). (D) Representative images of liver sections after H&E and Sirius Red staining; bar (200 μm). Sirius Red quantifications are shown each picture. Student’s t test; *P ≤ .05 vs control mice, #P ≤ .05 vs HFD-fed mice. (E) Hydroxyproline quantification in liver samples from treated mice. Student’s t test; *P ≤ .05 vs control mice, #P ≤ .05 vs HFD-fed mice; n = 5–14. (F) NAFLD activation score, composed by (G) steatosis, (H) lobular inflammation, and (I) hepatocellular ballooning, was evaluated in liver samples from treated mice. One-way analysis of variance; Student’s t test; *P ≤ .05 vs HFD-fed mice; n = 5–14.